Save information for later
Sign Up

Learn About Metachromatic Leukodystrophy

What is the definition of Metachromatic Leukodystrophy?

Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. Sulfatide accumulation in myelin-producing cells causes progressive destruction of white matter (leukodystrophy) throughout the nervous system, including in the brain and spinal cord (the central nervous system) and the nerves connecting the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound (the peripheral nervous system).

What are the causes of Metachromatic Leukodystrophy?

Most individuals with metachromatic leukodystrophy have mutations in the ARSA gene, which provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell's recycling centers. Within lysosomes, arylsulfatase A helps break down sulfatides.

How prevalent is Metachromatic Leukodystrophy?

Metachromatic leukodystrophy is reported to occur in 1 in 40,000 to 160,000 individuals worldwide. The condition is more common in certain genetically isolated populations: 1 in 75 in a small group of Jews who immigrated to Israel from southern Arabia (Habbanites), 1 in 2,500 in the western portion of the Navajo Nation, and 1 in 8,000 among Arab groups in Israel.

Is Metachromatic Leukodystrophy an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Metachromatic Leukodystrophy Local Doctors?
Ingeborg Mann-Krageloh
Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Tuebingen, BW, DE 

Ingeborg Mann-Krageloh practices in Tuebingen, Germany. Ms. Mann-Krageloh is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. Her top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Pontocerebellar Hypoplasia, and Bone Marrow Transplant.

Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Milan, IT 

Francesca Fumagalli practices in Milan, Italy. Ms. Fumagalli is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. Her top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Tuebingen, BW, DE 

Samuel Groeschel practices in Tuebingen, Germany. Mr. Groeschel is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. His top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Pontocerebellar Hypoplasia, and Bone Marrow Transplant.

What are the latest Metachromatic Leukodystrophy Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

Summary: The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepo...

Who are the sources who wrote this article ?

Published Date: June 29, 2021
Published By: National Institutes of Health